Skip to main content
Top
Published in: Inflammation Research 6/2012

01-06-2012 | Original Research Paper

Role of NOD2 in regulating the immune response to Aspergillus fumigatus

Authors: Zhuo-zhe Li, Li-li Tao, Jing Zhang, Hui-jun Zhang, Jie-Ming Qu

Published in: Inflammation Research | Issue 6/2012

Login to get access

Abstract

Background

The nucleotide-binding oligomerization domain-2 (NOD2) is a type of intracellular receptor recognizing the cell wall molecules of bacteria and inducing the innate immune response. Its role in defense against fungal infection remains uncertain. We thus investigated the role of the NOD2/RIP2 pathway in host responses to Aspergillus fumigatus (Af) in RAW264.7 cells.

Methods

RAW264.7 cells were cultured and Af conidia were added to stimulate the cells. The dynamic mRNA and protein expressions of NOD2 and RIP2 kinase were examined by real-time PCR and Western blotting. The protein expressions of nuclear factor-kappaB (NF-κB) and pro-inflammatory tumor necrosis factor-alpha and interleukin-8 were also investigated. Specific siRNA for NOD2 was synthesized and used to confirm the effect of NOD2 in the immune response to Af conidia.

Results

The stimulation of the cell line by Af conidia resulted in a significantly increased expression of NOD2 protein and RIP2 kinase. The production of NF-κB and downstream cytokines were also increased simultaneously. On knockdown of the NOD2 using RNA interference, the activation of NF-κB was interrupted and the production of cytokines was reduced in the cell line stimulated by Af conidia.

Conclusion

These results suggested that Af conidia induced NF-κB activation in a NOD2-dependent manner, which potentially contributed to the innate immune response.
Literature
1.
go back to reference Salman N, Törün SH, Budan B, et al. Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation. Expert Rev Anti Infect Ther. 2011;9(3):307–15.PubMedCrossRef Salman N, Törün SH, Budan B, et al. Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation. Expert Rev Anti Infect Ther. 2011;9(3):307–15.PubMedCrossRef
2.
go back to reference Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–73.PubMedCrossRef Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–73.PubMedCrossRef
3.
go back to reference Steinbach WJ, Benjamin DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39(2):192–8.PubMedCrossRef Steinbach WJ, Benjamin DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39(2):192–8.PubMedCrossRef
4.
go back to reference Balloy V, Chignard M. The innate immune response to Aspergillus fumigatus. Microbes Infect. 2009;11(12):919–27.PubMedCrossRef Balloy V, Chignard M. The innate immune response to Aspergillus fumigatus. Microbes Infect. 2009;11(12):919–27.PubMedCrossRef
5.
go back to reference Yamamoto S, Ma X. Role of Nod2 in the development of Crohn’s disease. Microbes Infect. 2009;11(12):912–8.PubMedCrossRef Yamamoto S, Ma X. Role of Nod2 in the development of Crohn’s disease. Microbes Infect. 2009;11(12):912–8.PubMedCrossRef
6.
go back to reference Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003;4(7):702–7.PubMedCrossRef Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003;4(7):702–7.PubMedCrossRef
7.
go back to reference Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278(11):8869–72.PubMedCrossRef Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278(11):8869–72.PubMedCrossRef
8.
go back to reference Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem. 2003;278(8):5509–12.PubMedCrossRef Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem. 2003;278(8):5509–12.PubMedCrossRef
9.
go back to reference Magalhaes JG, Lee J, Geddes K, et al. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur J Immunol. 2011;41(5):1445–55.PubMedCrossRef Magalhaes JG, Lee J, Geddes K, et al. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur J Immunol. 2011;41(5):1445–55.PubMedCrossRef
10.
go back to reference Tigno-Aranjuez JT, Asara JM, Abbott DW. Inhibition of RIP2’s tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 2010;24(23):2666–77.PubMedCrossRef Tigno-Aranjuez JT, Asara JM, Abbott DW. Inhibition of RIP2’s tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 2010;24(23):2666–77.PubMedCrossRef
11.
go back to reference Zhang H-J, Qu J-M, Shao C-Z, et al. Aspergillus fumigatus conidia upregulates NOD2 protein expression both in vitro and in vivo. Acta Pharmacol Sin. 2008;29(10):1202–8.PubMedCrossRef Zhang H-J, Qu J-M, Shao C-Z, et al. Aspergillus fumigatus conidia upregulates NOD2 protein expression both in vitro and in vivo. Acta Pharmacol Sin. 2008;29(10):1202–8.PubMedCrossRef
12.
go back to reference Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011;106(4):699–712.PubMedCrossRef Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011;106(4):699–712.PubMedCrossRef
13.
go back to reference Bruns T, Peter J, Reuken PA, et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int. 2012; 32:223–230. Bruns T, Peter J, Reuken PA, et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int. 2012; 32:223–230.
14.
go back to reference Brenmoehl J, Herfarth H, Glück T, et al. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med. 2007;33(9):1541–8.PubMedCrossRef Brenmoehl J, Herfarth H, Glück T, et al. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med. 2007;33(9):1541–8.PubMedCrossRef
15.
go back to reference Shaw MH, Reimer T, Sánchez-Valdepeñas C, et al. T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat Immunol. 2009;10(12):1267–74.PubMedCrossRef Shaw MH, Reimer T, Sánchez-Valdepeñas C, et al. T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat Immunol. 2009;10(12):1267–74.PubMedCrossRef
16.
go back to reference Sabbah A, Chang TH, Harnack R, et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol. 2009;10(10):1073–80.PubMedCrossRef Sabbah A, Chang TH, Harnack R, et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol. 2009;10(10):1073–80.PubMedCrossRef
17.
18.
go back to reference Deshmukh HS, Hamburger JB, Ahn SH, et al. Critical role of NOD2 in regulating the immune response to Staphylococcus aureus. Infect Immun. 2009;77(4):1376–82.PubMedCrossRef Deshmukh HS, Hamburger JB, Ahn SH, et al. Critical role of NOD2 in regulating the immune response to Staphylococcus aureus. Infect Immun. 2009;77(4):1376–82.PubMedCrossRef
19.
go back to reference Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307(5710):731–4.PubMedCrossRef Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307(5710):731–4.PubMedCrossRef
20.
go back to reference Berrington WR, Iyer R, Wells RD, et al. NOD1 and NOD2 regulation of pulmonary innate immunity to Legionella pneumophila. Eur J Immunol. 2010;40(12):3519–27.PubMedCrossRef Berrington WR, Iyer R, Wells RD, et al. NOD1 and NOD2 regulation of pulmonary innate immunity to Legionella pneumophila. Eur J Immunol. 2010;40(12):3519–27.PubMedCrossRef
21.
go back to reference Shimada K, Chen S, Dempsey PW, et al. The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection. PLoS Pathog. 2009;5(4):e1000379.PubMedCrossRef Shimada K, Chen S, Dempsey PW, et al. The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection. PLoS Pathog. 2009;5(4):e1000379.PubMedCrossRef
22.
go back to reference Braedel S, Radsak M, Einsele H, et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol. 2004;125(3):392–9.PubMedCrossRef Braedel S, Radsak M, Einsele H, et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol. 2004;125(3):392–9.PubMedCrossRef
23.
go back to reference Chai LYA, Kullberg BJ, Vonk AG, et al. Modulation of Toll-like receptor 2 (TLR2) and TLR4 responses by Aspergillus fumigatus. Infect Immun. 2009;77(5):2184–92.PubMedCrossRef Chai LYA, Kullberg BJ, Vonk AG, et al. Modulation of Toll-like receptor 2 (TLR2) and TLR4 responses by Aspergillus fumigatus. Infect Immun. 2009;77(5):2184–92.PubMedCrossRef
24.
go back to reference Poole JA, Kielian T, Wyatt TA, et al. Organic dust augments nucleotide-binding oligomerization domain (NOD2) expression via an NF-{kappa}B pathway to negatively regulate inflammatory responses. Am J Physiol Lung Cell Mol Physiol. 2011; 301:L296–306. Poole JA, Kielian T, Wyatt TA, et al. Organic dust augments nucleotide-binding oligomerization domain (NOD2) expression via an NF-{kappa}B pathway to negatively regulate inflammatory responses. Am J Physiol Lung Cell Mol Physiol. 2011; 301:L296–306.
25.
go back to reference Hu C, Sun L, Hu Y, et al. Functional characterization of the NF-kappaB binding site in the human NOD2 promoter. Cell Mol Immunol. 2010;7(4):288–95.PubMedCrossRef Hu C, Sun L, Hu Y, et al. Functional characterization of the NF-kappaB binding site in the human NOD2 promoter. Cell Mol Immunol. 2010;7(4):288–95.PubMedCrossRef
Metadata
Title
Role of NOD2 in regulating the immune response to Aspergillus fumigatus
Authors
Zhuo-zhe Li
Li-li Tao
Jing Zhang
Hui-jun Zhang
Jie-Ming Qu
Publication date
01-06-2012
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 6/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-012-0456-4

Other articles of this Issue 6/2012

Inflammation Research 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine